A

Amgen

Makes biotech medicines for serious illnesses

Global Insights Senior Manager - Oncology

Full-TimeUpdated on 10/22/2026Deadline 11/15/26
$162.5k - $219.8k+ Discretionary annual bonus + Stock-based long-term incentives
Mid
Bachelor's, Master's, PhD, Associate's
Thousand Oaks, CA, USA+1 moreMore locations: Oak Park, IL, USA
HybridFlex commuter / hybrid work model.
Growth & MarketingMarketing Generalist & Management

About the job

Requirements
  • Doctorate degree and 2 years of market research and/or analytics experience, or a master's degree and 4 years of market research and/or analytics experience, or a bachelor's degree and 6 years of market research and/or analytics experience, or an associate's degree and 10 years of market research and/or analytics experience, or a high school diploma or GED and 12 years of market research and/or analytics experience.
Responsibilities
  • Lead and contribute to integrated insight agendas across priority brands, pipeline assets, disease areas, and cross-portfolio initiatives; identify high-value business questions and translate them into decision-focused insight plans.
  • Synthesize information from market research, competitive intelligence, secondary data, advisory boards, and internal knowledge to develop strategic insights that address business needs.
  • Lead ad hoc strategic secondary analytics and ensure secondary data, analytics, and market evidence are integrated with primary research and competitive intelligence into evidence-based insight narratives and strategic recommendations.
  • Integrate insights and knowledge to develop business cases and facilitate workshops supporting clinical development plans, lifecycle management, and other strategic decisions, including critical go/no-go decisions and senior leadership presentations.
  • Plan, design, and lead primary market research with research agencies for assets across product lifecycle phases to enable strategic decision making.
  • Develop expertise across assigned oncology priorities, building understanding of relevant markets, customers, disease areas, and business context to serve as an insights partner and connect human insights to brand strategy and customer experience.
  • Partner with commercial leadership and cross-functional teams to define and prioritize objectives, evidence needs, budgets, and work plans; lead alignment on insight implications and recommended actions; and direct insight generation toward evolving portfolio priorities.
  • Communicate insights and recommendations to influence brand decision-making, including with senior leadership, and serve as a constructive devil’s advocate when needed.
  • Connect insights and identify patterns across brands, disease areas, and markets, bringing forward transferable learnings, emerging opportunities, and implications not visible within individual asset teams.
  • Identify, evaluate, and manage vendor relationships; lead agency teams and direct project-resource allocation to deliver high-value work.
  • Informally coach Managers and project teams in problem framing, research design, synthesis, and executive communication; promote knowledge exchange across Global Insights; and contribute to developing insight methods, marketing excellence, and AI-enabled insights capabilities.
  • Maintain rigor and attention to detail in insight generation and communication; ensure accuracy, consistency, and quality of evidence and recommendations; and ensure projects comply with Amgen standard operating procedures and meet quality, timeliness, and budget expectations.
Desired Qualifications
  • Demonstrated business acumen, strategic and critical thinking, and ability to influence key decisions.
  • Ability to rapidly build expertise and trusted cross-functional relationships in new business areas, navigate ambiguity, and flex across priorities, stakeholders, and workstreams.
  • Ability to independently own an integrated insight agenda and translate human, market, and analytical insights into brand narratives, customer experiences, and strategic recommendations.
  • Experience integrating secondary analytics, market data, and primary research into an insight narrative that enables strategic decision making.
  • Strong understanding of marketing strategy, including market research design, Jobs-to-Be-Done methodologies, identification of moments that matter, and brand-building.
  • Ability to operate in a fast-paced, evolving environment and reprioritize insight plans as evidence, launch needs, and business decisions evolve.
  • Analytical rigor and attention to detail, including ability to extract, analyze, treat, and consolidate data accurately and translate findings into actionable recommendations.
  • Oral, written, and presentation skills to explain complex concepts clearly to varied audiences, including senior management.
  • Coaching and resource leadership, including developing others and leading agency or matrixed project teams.
  • Knowledge of drug development, commercialization, and the healthcare industry, including patients, healthcare professionals, and payers.
  • Oncology experience; global launch preparation and/or late-stage pipeline commercialization is a plus.
  • Experience leading primary research and managing multiple stakeholders, work plans, budgets, and projects in parallel.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

Yahoo Finance
Oct 21st, 2026
Amgen's focus shifts to six growth drivers and MariTide as rare disease sales hit $1.6B

Amgen now frames its story around six key growth drivers, which grew 26% from a year earlier in fiscal Q2 2026 and made up nearly 70% of product sales. Rare disease, once reported on its own, is one of the six. The rare disease portfolio grew 21% to $1.6 billion, about 16% of quarterly revenue. Total revenue rose 9.5%, and management raised its 2026 revenue guidance to between $38.2 billion and $39.4 billion. Management also highlighted MariTide, an obesity drug in Phase III trials. Amgen wants it to be the first monthly or less frequent obesity therapy and is already scaling up manufacturing. One risk sits in rare disease. On September 1, 2026, Britain's medicines regulator suspended Tavneos for new patients, citing an unreliable main study. The drug made $119 million in fiscal Q1 2026. Amgen's next report is expected around November 3, 2026.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Amgen raises 2026 revenue forecast to $38.8B as shares gain 15.2%

Amgen raised its fiscal 2026 revenue forecast on August 4 to $38.8 billion at the midpoint, up 2.6% from $37.8 billion. Adjusted earnings per share guidance rose to $22.90 from $22.40. Six key growth drugs grew 26% from a year earlier and made up nearly 70% of product sales in the June quarter. Repatha sales rose 37% to $953 million, offsetting a 33% drop in Prolia and XGEVA sales as biosimilar copies launched. Total revenue rose 10%. The stock has gained 15.2% since the release, against 1.9% for the S&P 500. It closed at $434.03 on October 15, above both its 50-day and 200-day averages. Reaching the midpoint requires $20.1 billion in the second half. Amgen's next report is expected around November 3.

Yahoo Finance
Oct 8th, 2026
Amgen invests $2.6B in manufacturing for MariTide obesity drug ahead of Phase III results

Amgen is testing MariTide, an experimental obesity drug designed to be dosed monthly or less frequently. The therapy has advanced into late-stage Phase III trials, with nine studies currently running and three more planned. Executives reported strong enrolment during the company's second-quarter 2026 earnings call on 4 August 2026. Amgen expects capital spending of about $2.6 billion in 2026, partly to scale manufacturing capacity for MariTide's eventual launch. The company is investing across its US manufacturing sites in North Carolina, Ohio, and Puerto Rico. Amgen stock has returned 44% over the past twelve months, outpacing the S&P 500's 17.1% gain. The company reported $38.1 billion in revenue over the last twelve months, up from $34.9 billion a year earlier.

Yahoo Finance
Sep 29th, 2026
Amgen lifts dividend 6%, but eroding Prolia and Enbrel sales shift focus to MariTide Phase 3

Amgen raised its quarterly dividend 6% to $2.52 per share, marking its 14th consecutive annual increase since starting payouts in 2011. The biotech now pays $10.08 annually, yielding 2.36% at current share prices of $418.13. The dividend appears well covered. Amgen generated $8.1 billion in free cash flow in 2025 against $5.1 billion in dividend payments. Second quarter 2026 free cash flow reached $3.5 billion whilst dividends consumed $1.4 billion. However, biosimilar competition is eroding legacy revenue. Prolia and XGEVA sales dropped 33% whilst Enbrel fell 37%. The company carries $57 billion in debt. Future dividend growth may hinge on Phase 3 results for MariTide, Amgen's obesity candidate. The company follows a steady raise pattern similar to Johnson & Johnson, contrasting with Pfizer's post-COVID payout struggles.